spacer
home > ebr > summer 2002 > where is the blockbuster market heading?
PUBLICATIONS
European Biopharmaceutical Review

Where is the Blockbuster Market Heading?

The success of large pharmaceutical companies primarily reflects their development and marketing of blockbuster drugs - products that achieve annual revenues in excess of US$1 billion. This has led companies to follow growth strategies that rely heavily on finding new blockbusters, rightly believing that these products can offer significantly higher returns than their lower value counterparts. Increasing sales potential is critical as the average cost of developing a new molecular entity is currently approximately US$637 million. Coupled with the fact that only one in 5,000 to 10,000 lead compounds eventually reaches market after 14 years in R&D and regulatory reviews, a drug with annual revenues above US$1 billion is clearly able to recover a greater proportion of these costs. This improves R&D productivity and contributes to company margin growth.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Linda McNamara, Healthcare Strategy Analyst at Datamonitor

Dr Linda McNamara is a Healthcare Strategy Analyst at Datamonitor. Her work has appeared in the Wall Street Journal, Forbes and MedAd News. Prior to this position, she managed the musculoskeletal and central nervous system 'real-time knowledge' platforms from the onset of a Datamonitor/Sela joint venture, analysing clinical and commercial current affairs.
Before joining Datamonitor, Linda managed a neurosurgical regional unit in a major London teaching hospital for four years. She holds a PhD in Chemistry from University College London, and has written for the academic publications Tetrahedron Letters and Journal of Organic Chemistry.

spacer
Dr Linda McNamara
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

RSSL introduces same-day mycoplasma testing service in UK

RSSL

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement